
Explore how very high-risk localized prostate cancer is defined and treated, plus why PSMA PET findings shouldn’t automatically rule out curative therapy.

Explore how very high-risk localized prostate cancer is defined and treated, plus why PSMA PET findings shouldn’t automatically rule out curative therapy.

Tamim Niazi, MDCM, unpacks the interim DASL-HiCaP data, why conventional imaging was the chosen yardstick, and how to frame 96 weeks of therapy for patients.

Timam Niazi, MD, explains how DASL-HiCaP's salvage data sit alongside EMBARK, how his center chooses between surgery and radiation, and what the field must answer next.